Insurance Denial for Intravenous Immunoglobulin Therapy Effects Patients with Autoimmune Gastrointestinal Dysmotility

Title

Insurance Denial for Intravenous Immunoglobulin Therapy Effects Patients with Autoimmune Gastrointestinal Dysmotility

Creator

Edelbrock R; Owendoff G; Yan C; Wilson R

Publisher

Neurology

Date

2019
2019-04

Description

Objective: To identify the frequency of insurance related issues with intravenous immunoglobulin (IVIg) therapy approval for patients with autoimmune gastrointestinal dysmotility (AGID) and the outcomes of missed IVIg treatments.

Subject

Neurosciences & Neurology

Search for Full-text

Users with a NEOMED Library login can search for full-text journal articles at the following url: https://libraryguides.neomed.edu/home

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

2-2

Issue

15

Volume

92

Citation

Edelbrock R; Owendoff G; Yan C; Wilson R, “Insurance Denial for Intravenous Immunoglobulin Therapy Effects Patients with Autoimmune Gastrointestinal Dysmotility,” NEOMED Bibliography Database, accessed January 15, 2021, https://neomed.omeka.net/items/show/6485.

Social Bookmarking